Table 3 Incidence of toxicities at least possibly related to one or both of the study drugs

	Selumetinib related		Cixutumumab related		Common to both drugs
Adverse event	All grades	Grade ⩾3	All grades	Grade ⩾3	All grades	Grade ⩾3
Dermatologic^a					23 (77%)	0
GI (all)	21 (70%)	1 (3%)
Abdominal pain	5 (17%)	0
Nausea/vomiting	15 (50%)	1 (3%)
Constipation	2 (7%)	0
Diarrhoea	13 (43%)	0
Mucosal irritation^b					16 (53%)	0
Ophthalmologic symptoms^c	12 (40%)	2 (7%)
Poor appetite/weight loss					11 (37%)	0
Peripheral oedema	7 (23%)	0
Fatigue					6 (20%)	0
Hyperglycaemia			5 (17%)	4 (13%)
Neurologic
Confusion			1 (3%)	0
Dizziness			3 (10%)	0
Headache			5 (17%)	0
Gait disturbance			2 (7%)	0
Tinnitus			1 (3%)	0
Haematologic
Anaemia			4 (13%)	0
Leucopenia/neutropenia			2 (7%)	0
Bleeding			1 (3%)	0
Thrombosis (cerebrovascular accident)			2 (7%)	1 (3%)
Myalgias/arthralgias			3 (10%)	0
Hypertension					3 (10%)	2 (7%)
Cough	3 (10%)	0
Elevated creatinine			3 (10%)	0
Thrush					2 (7%)	0

Note: Data reported as n, the number of patients who reported the symptom at least once, and % of total patients reporting symptom unless otherwise noted. Adverse events deemed possibly, probably, or likely attributable to study drugs are included here.
^aIncludes acneiform rash, eczematous rash, drying/cracking skin and fingernails with superimposed infections, itching, hypopigmentation.
^bDry mouth, vaginal irritation, oral ulcers, erythema around eyes, denuded nasal epithelium, rhinitis.
^cBlurry vision, floaters, flashing lights, black dots/lines in field of vision, retinopathy.

Quick links

Search